A novel series of 3-arylbenzylidene-1H-benzo[4,5] imidazo[2,1-c][1,4]oxazine-1,4(3H)-dione (4a-l) was synthesized in moderate to good yields. The structures of the newly synthesized compounds were confirmed by 1H NMR, 13C NMR mass spectrometry and elemental analysis. The synthesized compounds were evaluated for their anti-bacterial and anti-oxidant activities. Among all the derivatives tested, the compound 3-(3,5- dimethoxy benzylidene)-1H-benzo [4,5]imidazo[2,1- c][1,4]oxazine-1,4-(3H)-dione showed more potent activity and 3-(4-methoxybenzylidene)-1H benzo[4,5] imidazo[2,1-c][1,4]oxazine-1,4(3H)-dion exhibited good activity as compared to standard streptomycin. The anti-fungal activity reveals that the compound 3- (3,5-dimethoxy benzylidene)-1H-benzo[4,5]imidazo [2,1-c][1,4]oxazine-1,4-(3H)-dione showed more promising activity as compared to standard Itrazole. The remaining compounds showed moderate to poor activity. Similarly, the anti-oxidant activity results revealed that the compound 3-(3,5-dimethoxy benzylidene)-1H-benzo [4,5] imidazo[2,1-c][1,4] oxazine-1,4-(3H)-dione exhibited potent activity as compared to the other tested compounds.
Conjugation of a novel histidine derivative to biomolecules and labelling with [99mTc(OH2)3(CO)3]+Electronic supplementary information (ESI) available: complete 1H and 13C NMR spectra of 14, 15, 16 and 19. See http://www.rsc.org/suppdata/ob/b4/b405575f/